NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,812.40+₹51.40 (+2.92%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.48% below the high.
Loading market information…
NSE · NECLIFE.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:19 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Nectar Lifesciences Limited’s quoted price sits in the lower half of its reported 52-week range, 55.04% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Nectar Lifesciences Limited’s forward annual dividend is ₹4.32 per share, paid annual. The forward yield is 42.64% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nectar Lifesciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing services (CRAMS), encompassing process innovation, optimization, and validation, along with production scale-up. This includes the preparation and global submission of drug master files (DMFs) and certificates of suitability, multi-kilo pilot plant manufacturing, large-scale bulk production, and chiral resolution. The company also offers specialized services in chemical and analytical development, as well as providing analytical, manufacturing, and engineering consulting. NLL's product range features a variety of active pharmaceutical ingredients (APIs) and intermediates, prominently including numerous cephalosporin compounds like cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. Additionally, Nectar Lifesciences engages in contract manufacturing for finished dosage forms, producing items such as tablets, capsules, dry powder oral suspensions, granules, and injectables, particularly for cephalosporin medications. Beyond its core pharmaceutical offerings, the company also supplies diagnostic tools, empty hard gelatin capsules, and menthol products.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:21 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
KEEP COMPARING
₹1,812.40+₹51.40 (+2.92%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.48% below the high.
₹9,811.00+₹147.00 (+1.52%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 0.35% below the high.
₹448.50-₹8.50 (-1.86%)
Bafna Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 6.55% below the high.
₹136.08-₹0.46 (-0.34%)
ZIM Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 14.85% below the high.
₹128.33+₹0.00 (0.0%)
Valiant Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 9.23% below the high.
₹449.50+₹21.40 (+5.0%)
Universus Photo Imagings Limited’s quoted price sits in the upper half of its reported 52-week range, 28.05% below the high.
₹110.75-₹0.09 (-0.08%)
Aarey Drugs & Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 3.53% below the high.
₹62.40-₹1.44 (-2.26%)
Brooks Laboratories Limited’s quoted price sits in the lower half of its reported 52-week range, 46.21% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
